In another study with melanomas [52], differences in MHC-I expression have not been reported in pretreatment samples, but the expression of genes that are associated with antigen processing and presentation, including MHC-I genes, was increased in responders early during the course of anti-PD-1 therapy. This evidence concerns the gene PDCD1 and melanoma.